All In Biotech

Drug Trial Radar · NCT04588922

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies and High-Risk Newly Diagnosed AML

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

May 10, 2021

Primary completion

Dec 30, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Sellas Life Sciences GroupIndustry
Sponsor type
Industry
First posted
Oct 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory AML, Group 2 in patients with relapse/refractory lymphoma/CLL/SLL). The safety, tolerability, and antitumor activity of SLS009 in combination with venetoclax and azacitidine in patient with relapsed/refractory AML who have relapsed on or are refractory to venetoclax-based regimens are being assessed in five cohorts of the expansion Group 3. Groups 4 and 5 have been added to evaluate efficacy, safety, and tolerability of GFH009 in combination with venetoclax and azacitidine in newly diagnosed AML patients who are less likely to benefit from standard induction treatment with venetoclax plus HMA only regimens.

Conditions

  • Hematologic Malignancies

Interventions

  • SLS009Drug

    Solution for injection

  • venetoclaxDrug

    Tablets

  • azacitidineDrug

    Solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability: Dose Limiting Toxicities (DLTs)Time frame: 21 to 28 days
  2. Safety and Tolerability: adverse events (AEs)Time frame: approximately 2 years
  3. Efficacy: ORRTime frame: 2 years

Locations

32 sites in 2 countries. Site status is shown where the registry gives one.

  • O'Neal Comprehensive Cancer Center, University of Alabama

    Birmingham, Alabama · Recruiting

  • City of Hope - Phoenix

    Goodyear, Arizona · Recruiting

  • Mayo Clinic

    Phoenix, Arizona · Not yet recruiting

  • Honor Health

    Scottsdale, Arizona · Recruiting

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • Mayo Clinic

    Jacksonville, Florida · Not yet recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • City of Hope - Atlanta

    Newnan, Georgia · Recruiting

  • City of Hope - Chicago

    Zion, Illinois · Recruiting

  • Ochsner Clinic Foundation

    New Orleans, Louisiana · Terminated

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Not yet recruiting

  • Atlantic Health

    Morristown, New Jersey · Not yet recruiting

  • Clinical Research Alliance, Inc.

    Lake Success, New York · Terminated

  • New York - Presbyterian Hospital

    New York, New York · Terminated

  • UNC School of Medicine, Division of Hematology

    Chapel Hill, North Carolina · Recruiting

  • Bon Secours St. Francis Cancer Center

    Greenville, South Carolina · Recruiting

  • Baylor Scott & White Health

    Dallas, Texas · Recruiting

  • MD Anderson

    Houston, Texas · Recruiting

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Completed

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Completed

  • Affiliated Cancer Hospital of Chongqing University

    Chongqing, Chongqing Municipality, China · Withdrawn

  • Cancer prevention and treatment center of Sun Yat sen University

    Guangzhou, Guangdong, China · Completed

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Completed

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China · Completed

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Completed

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Completed

  • The First Affiliated Hospital Of Nanchang University

    Nanchang, Jiangxi, China · Completed

  • Shengjing Hospital Affiliated to China Medical University

    Shenyang, Liaoning, China · Completed

  • Linyi Cancer Hospital

    Linyi, Shandong, China · Completed

  • Blood disease hospital, Chinese Academy of Medical Science

    Tianjin, Tianjin Municipality, China · Completed

  • The Second Affiliated hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.